Ann: Race Appoints George Clinical for Phase 1 Trial of RC220, page-135

Do we know how the anti-cancer element will be measured? How will they be able to separate what cancer killing is doxo, and what is driven by bis? Will we benchmarking against CR/PRs etc of a large doxo dataset?

Some good questions raised above. If we are just proving out cardioprotection element initially, will the investment buzz follow through if that's the only element we can announce? As many have said previously, inc DT, there are a few cardioprotect drugs already, but they're not used much or not commercially significant (in the scheme of oncology). Then our results may be viewed as a bit, so what. But I'm super tired this morning, so apologies, I may just be off and have forgotten details of our 1a/b and whether there will be anything reported on the 'ACS' characteristics.

if Masons hypothesis above re CP dose > ACS dose, then readouts should be interesting!